|Bid||19.50 x 400|
|Ask||21.30 x 100|
|Day's range||19.50 - 20.23|
|52-week range||8.36 - 25.20|
|PE ratio (TTM)||N/A|
|Earnings date||6 Aug 2018 - 10 Aug 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||35.33|
Omeros Corporation (OMER) today announced that the first cohort of subjects has been dosed in the Company’s Phase 1 clinical trial, evaluating the lead phosphodiesterase 7 (PDE7) inhibitor in Omeros’ OMS527 program broadly targeting addictions and compulsive disorders. Inhibitors of PDE7 have been demonstrated to modulate the brain’s dopamine levels, widely recognized as central to both addictive and compulsive disorders. With preclinical data showing efficacy in multiple types of addiction and compulsive disorders, the initial target planned for OMS527 is nicotine addiction.
Omeros Corporation (OMER) today announced that it has obtained regulatory authority and ethics committee clearance to start the Phase 1 clinical trial evaluating its lead phosphodiesterase 7 (PDE7) inhibitor from the company’s OMS527 program. Omeros discovered the link between PDE7 and addiction, and the company holds broad patents internationally directed to PDE7 inhibitors for the treatment of all addictions and compulsive disorders.
Omeros Corporation (OMER) today announced that it has entered into a settlement agreement with Lupin Ltd. and its subsidiary Lupin Pharmaceuticals, Inc. (Lupin), resolving Omeros’ patent litigation against Lupin. The litigation concerned Lupin’s filing of an Abbreviated New Drug Application (ANDA) seeking approval from the U.S. Food and Drug Administration (FDA) to market a generic version of Omeros’ commercial drug OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1% / 0.3%.
The Seattle-based company said it had a loss of 62 cents per share. Losses, adjusted for non-recurring costs, came to 53 cents per share. The drug developer posted revenue of $1.6 million in the period. ...
Omeros Corporation today announced recent highlights and developments as well as financial results for the first quarter ended March 31, 2018, which include:
Omeros Corporation (OMER) today announced that the company will issue its first quarter 2018 financial results for the period ended March 31, 2018, on Thursday, May 10, 2018, after the market closes. Omeros management will host a conference call and webcast that day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results. To access the live and subsequently archived webcast of the conference call, go to Omeros’ website at www.omeros.com and go to “Events” under the Investors section of the website.
Omeros Corporation (OMER) today announced that the U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to OMS721 for the treatment of patients with high-risk hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), specifically those patients who have persistent TMA despite modification of immunosuppressive therapy. This is the second breakthrough therapy drug designation for OMS721, which last year received the designation from FDA for the treatment of Immunoglobulin A (IgA) nephropathy.
Omeros Corporation announced that the results of four real-world clinical studies evaluating the benefits of OMIDRIA® 1% / 0.3% were presented at the American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting held in Washington, D.C., April 13-17, 2018.
Omeros Corporation today announced that the results of four studies directed to the benefits of OMIDRIA across a range of clinical situations in cataract surgery will be presented at the upcoming American Society of Cataract and Refractive Surgery Congress in Washington, D.C., April 13-17, 2018.
Omeros Corporation today announced that the Veterans Administration has added OMIDRIA® to the VA National Formulary.
In December 2017, the FDA approved Omeros’s supplemental new drug application for expanding the use of Omidria for pediatric use. Omidria prevents intraoperative miosis and also reduces post-operative pain for individuals undergoing cataract surgery and intraocular lens replacement. In January 2018, the European Medicines Agency’s Committee for Orphan Medicinal Products responded positively to Omeros’s application for orphan drug status for OMS721 for the treatment of primary immunoglobulin A nephropathy.
Omeros Corporation today announced that it has entered into an amendment to its existing credit facility with certain affiliates of CRG LP, a healthcare-focused investment firm.
Omeros (OMER) generated total revenue of $64.8 million in fiscal 2017, compared with $41.6 million in fiscal 2016. Between fiscal 2016 and fiscal 2017, Omeros’s product sale costs fell to $1 million from $1.4 million, and its SG&A (selling, general and administrative expenses) rose to $52 million from $43.7 million.
On a per-share basis, the Seattle-based company said it had a loss of 34 cents. Losses, adjusted for non-recurring costs, came to 25 cents per share. The drug developer posted revenue of $13.8 million ...
Omeros Corporation , a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for
Omeros Corporation today announced that the company will issue its fourth quarter and year-end 2017 financial results for the period ended December 31, 2017, on Thursday, March 1, 2018, after the market closes.